Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | NKT3964 |
| Trade Name | |
| Synonyms | NKT 3964|NKT-3964 |
| Drug Descriptions |
NKT3964 is a proteolysis-targeted chimera (PROTAC) that targets CDK2 for degradation, potentially resulting in decreased tumor cell proliferation and antitumor activity (Eur J Cancer 211 (2024): 114453). |
| DrugClasses | CDK2 Inhibitor 31 |
| CAS Registry Number | NA |
| NCIT ID | C213380 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| NKT3964 | NKT3964 | 0 | 1 |